Wilkin Timothy J., Gulick Roy M.
Cornell HIV Clinical Trials Unit, Division of International Medicine and Infectious Diseases, Weill Medical College of Cornell University, Box 566, 525 East 68th Street, New York, NY 10021, USA.
Curr Infect Dis Rep. 2003 Aug;5(4):339-348. doi: 10.1007/s11908-003-0012-z.
The major US treatment guidelines recently recommended starting antiretroviral therapy (ART) later in the course of HIV infection due to an increasing awareness of the difficulties associated with these regimens. Most of the data to support this change come from observational cohort studies. When deciding to start ART, a number of patient-specific factors and other issues should be considered. Given the many choices for initial ART, one should individualize the choice, taking into account antiretroviral regimen potency, durability, side effects, toxicities, and convenience to ensure a sustained clinical benefit for the patient.
由于越来越意识到这些治疗方案存在的困难,美国主要治疗指南最近建议在HIV感染过程中更晚开始抗逆转录病毒疗法(ART)。支持这一变化的大多数数据来自观察性队列研究。在决定开始ART时,应考虑一些患者特异性因素和其他问题。鉴于初始ART有多种选择,应根据抗逆转录病毒治疗方案的效力、持久性、副作用、毒性和便利性进行个体化选择,以确保患者获得持续的临床益处。